European Heart Journal - Cardiovascular Pharmacotherapy最新文献

筛选
英文 中文
STOPDAPT-3 subanalysis on prasugrel monotherapy after elective or emergent coronary intervention in patients with or without diabetes: are we ready for this? STOPDAPT-3子分析:无论是否患有糖尿病,在择期或紧急冠状动脉介入治疗后普拉格雷单药治疗:我们准备好了吗?
IF 5.3 1区 医学
European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-11-19 DOI: 10.1093/ehjcvp/pvae079
Jeehoon Kang, Giuseppe Gargiulo
{"title":"STOPDAPT-3 subanalysis on prasugrel monotherapy after elective or emergent coronary intervention in patients with or without diabetes: are we ready for this?","authors":"Jeehoon Kang, Giuseppe Gargiulo","doi":"10.1093/ehjcvp/pvae079","DOIUrl":"10.1093/ehjcvp/pvae079","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenetic testing to broaden patient eligibility for mavacamten. 通过药物基因检测,扩大患者使用马伐康坦的资格。
IF 5.3 1区 医学
European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-11-14 DOI: 10.1093/ehjcvp/pvae086
Lorenz Van der Linden, Lucas Van Aelst, Iacopo Olivotto
{"title":"Pharmacogenetic testing to broaden patient eligibility for mavacamten.","authors":"Lorenz Van der Linden, Lucas Van Aelst, Iacopo Olivotto","doi":"10.1093/ehjcvp/pvae086","DOIUrl":"10.1093/ehjcvp/pvae086","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness of Implementing a Genotype-Guided De-Escalation Strategy in Patients with Acute Coronary Syndrome. 对急性冠状动脉综合征患者实施基因型指导下的去梗策略的成本效益。
IF 5.3 1区 医学
European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-11-13 DOI: 10.1093/ehjcvp/pvae087
W W A van den Broek, Jaouad Azzahhafi, Dean R P P Chan Pin Yin, Niels M R van der Sangen, Shabiga Sivanesan, Lea M Dijksman, Ronald J Walhout, Melvyn Tjon Joe Gin, Nicoline J Breet, Jorina Langerveld, Georgios J Vlachojannis, Rutger J van Bommel, Yolande Appelman, Ron H N van Schaik, José P S Henriques, Wouter J Kikkert, Jurriën M Ten Berg
{"title":"Cost-effectiveness of Implementing a Genotype-Guided De-Escalation Strategy in Patients with Acute Coronary Syndrome.","authors":"W W A van den Broek, Jaouad Azzahhafi, Dean R P P Chan Pin Yin, Niels M R van der Sangen, Shabiga Sivanesan, Lea M Dijksman, Ronald J Walhout, Melvyn Tjon Joe Gin, Nicoline J Breet, Jorina Langerveld, Georgios J Vlachojannis, Rutger J van Bommel, Yolande Appelman, Ron H N van Schaik, José P S Henriques, Wouter J Kikkert, Jurriën M Ten Berg","doi":"10.1093/ehjcvp/pvae087","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvae087","url":null,"abstract":"<p><strong>Aims: </strong>A genotype-guided P2Y12-inhibitor de-escalation strategy, switching acute coronary syndrome (ACS) patients without a CYP2C19 loss-of-function allele from ticagrelor or prasugrel to clopidogrel, has shown to reduce bleeding risk without affecting effectivity of therapy by increasing ischemic risk. We estimated the cost-effectiveness of this personalized approach compared to standard dual antiplatelet therapy (DAPT; aspirin plus ticagrelor/prasugrel) in the Netherlands.</p><p><strong>Methods and results: </strong>We developed a one-year decision tree based on results of the FORCE-ACS registry, comparing a cohort of ACS patients who underwent genotyping with a cohort of ACS patients treated with standard DAPT. This was followed by a lifelong Markov model to compare lifetime costs, and quality-adjusted life years (QALYs) for a fictional cohort of 1000 patients. The cost-effectiveness analysis was performed from the perspective of the Dutch healthcare system. A genotype-guided de-escalation strategy led to anincrease of 55.30 QALYs and saved €698,286 compared to standard DAPT based on a lifetime horizon. Probabilistic sensitivity analysis showed that the genotype-guided strategy was cost-saving in 93% and increased QALYs in 86% of simulations. The intervention remained cost-effective in the scenario where prices for all P2Y12-inhibitors were equalized. The genotype-guided strategy remained dominant in various other scenario and sensitivity analyses.</p><p><strong>Conclusion: </strong>A genotype-guided de-escalation strategy in patients with ACS was both cost-saving and yielded higher QALYs compared to standard DAPT, highlighting its potential for implementation in clinical practice. Trial registration: ClinicalTrials.gov identifier: NCT03823547.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subcutaneous furosemide in heart failure: a systematic review. 心力衰竭患者皮下注射呋塞米:系统综述。
IF 5.3 1区 医学
European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-11-08 DOI: 10.1093/ehjcvp/pvae083
Joanna Osmanska, Mark C Petrie, Kieran F Docherty, Matthew M Y Lee, John J V McMurray, Ross T Campbell
{"title":"Subcutaneous furosemide in heart failure: a systematic review.","authors":"Joanna Osmanska, Mark C Petrie, Kieran F Docherty, Matthew M Y Lee, John J V McMurray, Ross T Campbell","doi":"10.1093/ehjcvp/pvae083","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvae083","url":null,"abstract":"<p><strong>Background and aim: </strong>Intravenous loop diuretics are the primary treatment for congestion in patients with decompensated heart failure (HF). Furosemide is the most commonly used loop diuretic and is licensed for administration either orally, intramuscularly or intravenously but not subcutaneously. Recently developed, pH-neutral, concentrated, 'skin-friendly' preparations of furosemide have been developed which allow subcutaneous administration. In this systematic review, we summarize and critically appraise the current evidence for subcutaneous furosemide in patients with HF.</p><p><strong>Methods and results: </strong>The electronic databases MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov registry were searched up to 31 December 2023. Of the 17 studies identified, 5 were randomised controlled trials (RCTs), 2 were non-randomised controlled studies, 3 were prospective observational cohort studies, and 7 were retrospective observational studies.All RCTs utilised novel pH-neutral, subcutaneous preparations of furosemide. Bioavailability of novel subcutaneous preparations were similar to intravenous furosemide 10 mg/ml: 99.7% for an 8 mg/ml preparation and 112% for a 30 mg/ml preparation. Natriuresis and diuresis were also similar with novel subcutaneous and conventional intravenous furosemide. Adverse events of novel preparations included infusion site pain or discomfort, localised skin erythema and minimal swelling. All studies of conventional subcutaneous furosemide were non-randomised with very limited data re bioavailability or diuretic and natriuretic effect. Conventional subcutaneous furosemide was associated with substantial skin irritation (affecting 3-23% of patients), and skin infections requiring treatment with antibiotics (3-17%).</p><p><strong>Conclusions: </strong>Novel, pH-neutral preparations of subcutaneous furosemide achieved similar diuresis, natriuresis, and bioavailability to intravenous furosemide, and were well tolerated. Novel preparations may be a treatment option for patients with HF.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis. PCSK9 抑制剂广泛降低低密度脂蛋白胆固醇对静脉血栓风险的影响
IF 5.3 1区 医学
European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-11-08 DOI: 10.1093/ehjcvp/pvae077
Shinya Goto, Shinichi Goto
{"title":"Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis.","authors":"Shinya Goto, Shinichi Goto","doi":"10.1093/ehjcvp/pvae077","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvae077","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial. 接受 PCI 治疗的老年 ACS 患者服用 60 毫克与 90 毫克替卡格雷:一项随机交叉试验。
IF 5.3 1区 医学
European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-11-06 DOI: 10.1093/ehjcvp/pvae054
Raffaele Piccolo, Fiorenzo Simonetti, Marisa Avvedimento, Maria Cutillo, Mario Enrico Canonico, Valeria Conti, Giuseppe Gargiulo, Roberta Paolillo, Fabrizio Dal Piaz, Amelia Filippelli, Bruno Charlier, Alessandra Spinelli, Stefano Cristiano, Plinio Cirillo, Luigi Di Serafino, Anna Franzone, Giovanni Esposito
{"title":"Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial.","authors":"Raffaele Piccolo, Fiorenzo Simonetti, Marisa Avvedimento, Maria Cutillo, Mario Enrico Canonico, Valeria Conti, Giuseppe Gargiulo, Roberta Paolillo, Fabrizio Dal Piaz, Amelia Filippelli, Bruno Charlier, Alessandra Spinelli, Stefano Cristiano, Plinio Cirillo, Luigi Di Serafino, Anna Franzone, Giovanni Esposito","doi":"10.1093/ehjcvp/pvae054","DOIUrl":"10.1093/ehjcvp/pvae054","url":null,"abstract":"<p><strong>Aims: </strong>Although dual antiplatelet therapy with aspirin and a potent P2Y12 receptor inhibitor is currently recommended in patients with acute coronary syndrome (ACS), its use in elderly patients remains challenging. The aim of this trial is to evaluate the pharmacodynamic and pharmacokinetic profile of ticagrelor 60 vs. 90 mg twice daily among elderly patients (≥75 years) with ACS undergoing percutaneous coronary intervention (PCI).</p><p><strong>Methods and results: </strong>PLINY The ELDER (NCT04739384) was a randomized, crossover trial testing the non-inferiority of a lower vs. standard dose of ticagrelor with respect to the primary endpoint of P2Y12 inhibition as determined by pre-dose P2Y12 reaction units (PRU) using the VerifyNow-P2Y12 (Accumetrics, San Diego, CA, USA). Other pharmacodynamic tests included light transmittance aggregometry, multiple electrode aggregometry, and response to aspirin. Plasma levels of ticagrelor and its active metabolite AR-C124910XX were also evaluated. A total of 50 patients (mean age 79.6 ± 4.0 years, females 44%) were included in the trial. Ticagrelor 60 mg was non-inferior to ticagrelor 90 mg according to VerifyNow-P2Y12 results (PRU 26.4 ± 32.1 vs. 30.4 ± 39.0; least squares mean difference: -4; 95% confidence interval: -16.27 to 8.06; P for non-inferiority = 0.002). Other pharmacodynamic parameters were similar between the two ticagrelor doses and there were no differences in response to aspirin. Plasma levels of ticagrelor (398.29 ± 312.36 ng/mL vs. 579.57 ± 351.73 ng/mL, P = 0.006) and its active metabolite were significantly lower during treatment with ticagrelor 60 mg.</p><p><strong>Conclusion: </strong>Although plasma concentrations were lower, ticagrelor 60 mg twice daily provided a similar magnitude of platelet inhibition compared with ticagrelor 90 mg twice daily among elderly patients undergoing PCI.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"578-587"},"PeriodicalIF":5.3,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141723336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation. 欧安会心血管药物疗法工作组:通过变革保持连续性。
IF 5.3 1区 医学
European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-11-06 DOI: 10.1093/ehjcvp/pvae070
Dobromir Dobrev, Bianca Rocca, Juan-Carlos Kaski
{"title":"The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation.","authors":"Dobromir Dobrev, Bianca Rocca, Juan-Carlos Kaski","doi":"10.1093/ehjcvp/pvae070","DOIUrl":"10.1093/ehjcvp/pvae070","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"571"},"PeriodicalIF":5.3,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis. 抗血栓治疗与体重的最新进展。ESC心血管药物治疗工作组和ESC血栓形成工作组临床共识声明。
IF 5.3 1区 医学
European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-11-06 DOI: 10.1093/ehjcvp/pvae064
Bruna Gigante, Juan Tamargo, Stefan Agewall, Dan Atar, Jurrien Ten Berg, Gianluca Campo, Elisabetta Cerbai, Christina Christersson, Dobromir Dobrev, Péter Ferdinandy, Tobias Geisler, Diana A Gorog, Erik L Grove, Juan Carlos Kaski, Andrea Rubboli, Sven Wassmann, Håkan Wallen, Bianca Rocca
{"title":"Update on antithrombotic therapy and body mass: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and the European Society of Cardiology Working Group on Thrombosis.","authors":"Bruna Gigante, Juan Tamargo, Stefan Agewall, Dan Atar, Jurrien Ten Berg, Gianluca Campo, Elisabetta Cerbai, Christina Christersson, Dobromir Dobrev, Péter Ferdinandy, Tobias Geisler, Diana A Gorog, Erik L Grove, Juan Carlos Kaski, Andrea Rubboli, Sven Wassmann, Håkan Wallen, Bianca Rocca","doi":"10.1093/ehjcvp/pvae064","DOIUrl":"10.1093/ehjcvp/pvae064","url":null,"abstract":"<p><p>Obesity and underweight are a growing health problem worldwide and a challenge for clinicians concerning antithrombotic therapy, due to the associated risks of thrombosis and/or bleeding. This clinical consensus statement updates a previous one published in 2018, by reviewing the most recent evidence on antithrombotic drugs based on body size categories according to the World Health Organization classification. The document focuses mostly on individuals at the extremes of body weight, i.e. underweight and moderate-to-morbid obesity, who require antithrombotic drugs, according to current guidelines, for the treatment or prevention of cardiovascular diseases or venous thromboembolism. Managing antithrombotic therapy or thromboprophylaxis in these individuals is challenging, due to profound changes in body composition, metabolism and organ function, and altered drug pharmacokinetics and pharmacodynamics, as well as weak or no evidence from clinical trials. The document also includes artificial intelligence simulations derived from in silico pharmacokinetic/pharmacodynamic models, which can mimic the pharmacokinetic changes and help identify optimal regimens of antithrombotic drugs for severely underweight or severely obese individuals. Further, bariatric surgery in morbidly obese subjects is frequently performed worldwide. Bariatric surgery causes specific and additional changes in metabolism and gastrointestinal anatomy, depending on the type of the procedure, which can also impact the pharmacokinetics of antithrombotic drugs and their management. Based on existing literature, the document provides consensus statements on optimizing antithrombotic drug management for underweight and all classes of obese patients, while highlighting the current gaps in knowledge in these complex clinical settings, which require personalized medicine and precision pharmacology.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"614-645"},"PeriodicalIF":5.3,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiplatelet treatment, dyslipidemia, cardiac side events during COVID-19 vaccine, antithrombotic treatment with different BMI. 不同体重指数下的抗血小板治疗、血脂异常、COVID-19 疫苗接种期间的心脏副作用、抗血栓治疗。
IF 5.3 1区 医学
European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-11-06 DOI: 10.1093/ehjcvp/pvae072
Stefan Agewall
{"title":"Antiplatelet treatment, dyslipidemia, cardiac side events during COVID-19 vaccine, antithrombotic treatment with different BMI.","authors":"Stefan Agewall","doi":"10.1093/ehjcvp/pvae072","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvae072","url":null,"abstract":"","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":"10 7","pages":"569-570"},"PeriodicalIF":5.3,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of dyslipidaemia in patients with comorbidities: facing the challenge. 合并症患者的血脂异常管理--面对挑战。
IF 5.3 1区 医学
European Heart Journal - Cardiovascular Pharmacotherapy Pub Date : 2024-11-06 DOI: 10.1093/ehjcvp/pvae058
Gert Mayer, Dobromir Dobrev, Juan Carlos Kaski, Anne Grete Semb, Kurt Huber, Andreas Zirlik, Stefan Agewall, Heinz Drexel
{"title":"Management of dyslipidaemia in patients with comorbidities: facing the challenge.","authors":"Gert Mayer, Dobromir Dobrev, Juan Carlos Kaski, Anne Grete Semb, Kurt Huber, Andreas Zirlik, Stefan Agewall, Heinz Drexel","doi":"10.1093/ehjcvp/pvae058","DOIUrl":"10.1093/ehjcvp/pvae058","url":null,"abstract":"<p><p>Dyslipidaemia is a common chronic kidney disease (CKD) and contributes to excessively elevated cardiovascular mortality. The pathophysiology is complex and modified by comorbidities like the presence/absence of proteinuria, diabetes mellitus or drug treatment. This paper provides an overview of currently available treatment options. We focused on individuals with CKD and excluded those on renal replacement therapy (haemodialysis, peritoneal dialysis, or kidney transplantation). The use of statins is safe and recommended in most patients, but guidelines vary with respect to low-density lipoprotein (LDL) cholesterol goals. While no dedicated primary or secondary prevention studies are available for pro-protein convertase subtilisin/kexin type 9 inhibitors, secondary analyses of large outcome trials reveal no effect modification on endpoints by the presence of CKD. Similar data have been shown for bempedoic acid, but no definite conclusion can be drawn with respect to efficacy and safety. No outcome trials are available for inclisiran while the cholesterol lowering effects seem to be unaffected by CKD. Finally, the value of fibrates and icosapent ethyl in CKD is unclear. Lipid abnormalities contribute to the massive cardiovascular disease burden in CKD. Lowering of LDL cholesterol with statins (and most likely PCSK9 inhibitors) reduces the event rate and thus statin therapy should be initiated in almost all individuals. Other interventions (bempedoic acid, inclisiran, fibrates, or icosapent ethyl) currently need a case-by-case decision before prescription.</p>","PeriodicalId":11982,"journal":{"name":"European Heart Journal - Cardiovascular Pharmacotherapy","volume":" ","pages":"608-613"},"PeriodicalIF":5.3,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141995594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信